Select Language
TROP-2
TROP-2 Overview
| English Name | Tumor-associated calcium signal transducer 2 | Approved Drugs | 3 |
| Drugs in Clinical Trials | 27 | Target Synonym | Tumor-associated calcium signal transducer 2，M1S1，TROP2，TACSTD2，Pancreatic carcinoma marker protein GA733-1，Tumor Associated Calcium Signal Transducer 2，GA733-1，Membrane Component， Chromosome 1， Surface Marker 1，Gastrointestinal Tumor-Associated Antigen GA7331，Pancreatic Carcinoma Marker Protein GA7331，Cell surface glycoprotein Trop-2，Membrane component chromosome 1 surface marker 1，40kD Glycoprotein， Identified By Monoclonal Antibody GA733，Cell Surface Glycoprotein TROP2，Epithelial Glycoprotein-1，Truncated TACSTD2，GA7331，EGP-1，EGP1，GP50，Trophoblast Cell Surface Antigen 2 |
| Highest Development Stage | Approved | ||
| English Name | Tumor-associated calcium signal transducer 2 |
| Target Synonym | Tumor-associated calcium signal transducer 2，M1S1，TROP2，TACSTD2，Pancreatic carcinoma marker protein GA733-1，Tumor Associated Calcium Signal Transducer 2，GA733-1，Membrane Component， Chromosome 1， Surface Marker 1，Gastrointestinal Tumor-Associated Antigen GA7331，Pancreatic Carcinoma Marker Protein GA7331，Cell surface glycoprotein Trop-2，Membrane component chromosome 1 surface marker 1，40kD Glycoprotein， Identified By Monoclonal Antibody GA733，Cell Surface Glycoprotein TROP2，Epithelial Glycoprotein-1，Truncated TACSTD2，GA7331，EGP-1，EGP1，GP50，Trophoblast Cell Surface Antigen 2 |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 27 |
| Highest Development Stage | Approved |
TROP-2 Product List
- Product Category
Protein (18)Beads (1)Antibody (1)Kits (1)
- Product Status
Launched (22)
- Species
Human (9)Mouse (4)Rhesus macaque (4)Canine (1)Rabbit (1)Cynomolgus (2)
- Tag
His Tag (8)His Tag & Avi Tag (5)Fc Tag (2)- (4)Fc Tag & Avi Tag (3)
- Conjugate
Unconjugated (11)Biotin-labeled (8)- (3)
Add to Cart
Total: 21
- 1
- 2
- 3
TROP-2 Background
TROP-2 is a single-copy gene in human cells, and encodes a type-1 transmembrane glycoprotein which is over-expressed in various malignancies, also referred to as tumor associated calcium signal transducer 2 (TACSTD2), GA733-1 or M1S1. TROP-2 is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. Trop-1 and Trop-2 are homologous to serum IGF-II-binding proteins and appear as signal transducers. Thus, they likely represent novel cell-surface receptors and may play a role in regulating the growth of carcinoma cells.
TROP-2 Synonyms
TACSTD2,GA733-1,M1S1,TROP2
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| Trop2 ADC -01 | IND | ADC | Humanized Mouse | Solid Tumor | Non-small cell lung cancer,Pancreatic cancer |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SHR-A1921 | SHR-A1921; SHRA1921; SHR-1921 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
| ESG-401 | STI-3258; OQY-3258; ESG-401 | Phase 3 Clinical | Shanghai Escugen Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer | Details |
| FDA018 Antibody Drug Conjugate | FDA018-ADC; FDA-018-ADC | Phase 3 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
| GQ-1010 | PBI-410; GQ1010; BHV1510; BHV-1510; GQ-1010 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Trop2 CAR-NK cell therapy(Henan Provincial Cancer Hospital) | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung | Details | ||
| OBI-992 | BSI-992; BSI992; R-992; OBI-992 | Phase 2 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| JSKN-016 | JSKN016; JSKN-016 | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HS-20105 | HS-20105; HS20105 | Phase 2 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
| IBI130 | IBI130; IBI-130 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| Anti TROP2 antibody drug conjugate ADC（Fudan University） | Phase 2 Clinical | Fudan University | Triple Negative Breast Neoplasms | Details | |
| 9MW-2921 | 9MW2921; 9MW-2921 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
| MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| BAT-8008 | BAT-8008; BAT8008 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Triple Negative Breast Neoplasms | Details |
| DB-1305 | DB1305; BNT325; BNT-325; DB-1305 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
| BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| BL-M02D1 | Phase 2 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| LCB-84 | LCB-84 | Phase 2 Clinical | Legochem Biosciences Inc | Solid tumours | Details |
| JS-108 | DAC-002; JS-108; DAC-002/JS108 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms | Details |
| IBI-3007 | IBI3007; IBI-3007 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| HS-20124 | HS-20124; HS20124 | Phase 1 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
| IBR-822 | IBR822; IBR-822 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours | Details |
| DXC-1002 | DXC1002; DXC-1002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours | Details |
| DS-001 | DS001; DS-001 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Dartsbio Pharmaceuticals Ltd | Neoplasms | Details |
| FZ-AD004 | FZ-AD004 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details |
| U87 CAR-T cell therapy(Unicar-Therapy Bio-Medicine Technology) | U-87 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Head and Neck Neoplasms; Solid tumours; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
| BCG-011 | DM-001; BCG-011 | Phase 1 Clinical | Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| MT-302 | MT-302 | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132; IMMU-0132 | Approved | Immunomedics Inc, Gilead Sciences Inc | Trodelvy, 拓达维, TRODELVY | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Brain metastases; Mesothelioma; Urinary Bladder Neoplasms; Klatskin Tumor; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Hormone-Resistant Prostate Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours; Thyroid Carcinoma, Anaplastic; Salivary Gland Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
| Datopotamab deruxtecan | DS-1062a; DS-1062; Dato-DXd; S-1062a | Approved | Daiichi Sankyo Co Ltd | DATROWAY, Datroway | Japan | Breast Neoplasms | Daiichi Sankyo Co Ltd | 2024-12-27 | Solid tumours; Ovarian Neoplasms; Biliary Tract Neoplasms; Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Sacituzumab tirumotecan | SKB-264; MK-2870; SKB264; sac-TMT | Approved | Klus Pharma Inc | 佳泰莱 | Mainland China | Triple Negative Breast Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2024-11-22 | Small Cell Lung Carcinoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Metastatic breast cancer; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Biliary Tract Neoplasms | Details |
Product Reviews
W***A2025-11-07
0People LikeWe used products from many companies and finally chose this product, not only because the delivery time is relatively fast, but also because the product met experimental expectations. Multiple tests showed consistent effects, favorable price, and good service.- M***g2023-07-06 0People LikeThis protein was used to immunize mice for antibody development. Proteins were mixed with CFA/IFA and immunized intraperitoneally. Mice were boosted every 14 days for 5 boosts following initial immunization. Serum titers were measured by ELISA following Days 0, 43, and 65. Of the two mice immunized with this protein, only one mouse developed an antibody response as low signal was detected at day 65.
V***w2023-02-21 2People LikeAcro and their customer support are super helpful. Products ordered arrived in a timely manner. Customer support personal are as friendly as they are insightful. Never have they disappointed when purchasing any of their products. Such a user friendly website and if anything is not found customer support never backs down to help out! Acro’s personal are very friendly and knowledgeable. They were friendly and helpful when resolving this issue.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland